Ocugen, Inc. Form 4 (April 29, 2021) — Tammara Vijay

Summary

Vijay Tammara, Senior Vice President of Ocugen, Inc. (trading symbol OCGN), reports in this Form 4 option exercises under code M followed by sales under code S, effected under a Rule 10b5-1 trading plan. On 04/29/2021, shares acquired at $0.46, $2.94, $0.51 and $0.57 were sold as 9,000 shares at $10.97, 3,000 at $10.99, 12,880 at $10.96 and 5,111 at $10.96. On 05/03/2021, 4,317 shares were acquired at $0.46 and sold at $16. Table I shows no shares owned directly after each sale. The signature is /s/ Vijay Tammara by Sanjay Subramanian as attorney-in-fact, dated 05/03/2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Tammara Vijay (Last) (First) (Middle) C/O OCUGEN, INC. 263 GREAT VALLEY PARKWAY (Street) MALVERN PA 19355 (City) (State) (Zip) | Tammara Vijay | (Last) | (First) | (Middle) | C/O OCUGEN, INC. | 263 GREAT VALLEY PARKWAY | MALVERN | PA | 19355 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Ocugen, Inc. [ OCGN ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Senior Vice President | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | Senior Vice President
3. Date of Earliest Transaction
 (Month/Day/Year) 04/29/2021
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Comm Stock | 04/29/2021 | M | 9,000 | A | $ 0.46 | 9,000 | D
Common Stock | 04/29/2021 | S | 9,000 (1) | D | $ 10.97 (2) | 0 | D
Common Stock | 04/29/2021 | M | 3,000 | A | $ 2.94 | 3,000 | D
Common Stock | 04/29/2021 | S | 3,000 (1) | D | $ 10.99 | 0 | D
Common Stock | 04/29/2021 | M | 12,880 | A | $ 0.51 | 12,880 | D
Common Stock | 04/29/2021 | S | 12,880 (1) | D | $ 10.96 (3) | 0 | D
Common Stock | 04/29/2021 | M | 5,111 | A | $ 0.57 | 5,111 | D
Common Stock | 04/29/2021 | S | 5,111 (1) | D | $ 10.96 (4) | 0 | D
Common Stock | 05/03/2021 | M | 4,317 | A | $ 0.46 | 4,317 | D
Common Stock | 05/03/2021 | S | 4,317 (1) | D | $ 16 | 0 | D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Options (Right to Buy) | $ 0.46 | 04/29/2021 | M | 9,000 | (5) | 09/18/2024 | Common Stock | 9,000 | $ 0 | 9,217 | D
Options (Right to Buy) | $ 2.94 | 04/29/2021 | M | 3,000 | (5) | 04/26/2026 | Common Stock | 3,000 | $ 0 | 4,191 | D
Options (Right to Buy) | $ 0.51 | 04/29/2021 | M | 12,880 | (6) | 01/02/2030 | Common Stock | 12,880 | $ 0 | 64,761 | D
Options (Right to Buy) | $ 0.57 | 04/29/2021 | M | 5,111 | (7) | 08/14/2030 | Common Stock | 5,111 | $ 0 | 44,889 | D
Options (Right to Buy) | $ 0.46 | 05/03/2021 | M | 4,317 | (5) | 09/18/2024 | Common Stock | 4,317 | $ 0 | 4,900 | D
Explanation of Responses:
1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.86 to $11.06. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes (2) - (4) to this Form 4.
3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.86 to $11.07.
4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.86 to $11.07.
5. All of the options became exerciable immediately upon grant.
6. 34,507 shares under the option are exercisable. The option, initially representing a right to purchase a total of 77,641 shares, vests and becomes exercisable over three years commencing on January 2, 2021, subject to continued service with the Company on the applicable vesting dates.
7. 111,111 shares under the option are exercisable. The option, initially representing a right to purchase a total of 50,000 shares, vests and becomes exercisable over three years commencing on August 14, 2020, subject to continued service with the Company on the applicable vesting dates.
/s/ Vijay Tammara by Sanjay Subramanian, his attorney-in-fact | 05/03/2021
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_OCGN_4_filed2021-05-03_0001192482-21-000388.xml

Size

27,596 bytes

SHA-256

53987f51f3e2f5d39c2198f7aed8ff6692f7f5673882f6286096bcb8ad91ba4e

Our copy

SEC_OCGN_4_filed2021-05-03_0001192482-21-000388.xml

Original

www.sec.gov